Skip to main content
SpringerLink
Log in

Oral Pharmacotherapy for Male Sexual Dysfunction

A Guide to Clinical Management

  • Book
  • © 2005

Overview

Editors:
  1. Gregory A. Broderick

    1. Department of Urology, Mayo Clinic College of Medicine, Jacksonville

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Current Clinical Urology (CCU)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (19 chapters)

  1. Front Matter

    Pages i-xii
    Download chapter PDF

  2. Physiology and Pharmacology of Erectile Dysfunction

    • Rafael Carrion, Derek Bochinski, Nadeem Rahman, Tom Lue
    Pages 1-24

  3. Epidemiology of Erectile Dysfunction

    • Jonathan D. Schiff, John P. Mulhall
    Pages 25-42

  4. Pharmacology of Phosphodiesterase Inhibitors

    • Erwin Bischoff
    Pages 43-63

  5. Sildenafil Citrate, the Classic PDE5 Inhibitor

    • Harin Padma-Nathan
    Pages 65-83

  6. Tadalafil

    • Culley C. Carson III
    Pages 85-107

  7. Vardenafil Clinical Trials Experience

    • Ajay Nehra
    Pages 109-148

  8. Erectile Dysfunction Assessment and Management in Primary Care Practice

    • Louis Kuritzky, Martin Miner
    Pages 149-183

  9. When to Refer the Patient With Erectile Dysfunction to a Specialist

    • Ira D. Sharlip
    Pages 185-197

  10. Erectile Dysfunction

    • Thorsten Reffelmann, Robert A. Kloner
    Pages 199-220

  11. Is Diabetic Erectile Dysfunction More Difficult to Treat?

    • Pierre Theuma, Vivian A. Fonseca
    Pages 221-236

  12. Depression and Antidepressant-Associated Erectile Dysfunction

    • Raymond C. Rosen
    Pages 237-251

  13. Intracavernous, Transurethral, and Topical Therapies for Erectile Dysfunction in the Era of Oral Pharmacotherapy

    • Hans-Martin A. Fritsche, Mustafa F. Usta, Wayne J. G. Hellstrom
    Pages 253-277

  14. Androgen Deficiency in the Aging Male

    • Alvaro Morales, Jeremy P. W. Heaton
    Pages 279-299

  15. Central Activation of Erection and Clinical Experience

    • Jeremy P. W. Heaton, Alvaro Morales, Michael A. Adams
    Pages 301-322

  16. Sustaining the Cure

    • Ronald W. Lewis
    Pages 323-337

  17. Prevention and Treatment of Erectile Dysfunction Utilizing Lifestyle Changes and Dietary Supplements

    • Mark A. Moyad
    Pages 339-378

  18. Pharmacological Strategies in the Management of Rapid Ejaculation

    • Chris G. McMahon
    Pages 379-408

  19. Sexual Dysfunction After Radical Prostatectomy and the Use of PDE-5 Inhibitors

    • Andrew R. McCullough
    Pages 409-421

  20. Female Sexual Dysfunction

    • Ridwan Shabsigh, Anne R. Davis, Aristotelis G. Anastasiadis, Nawras Makhsida, Grace Yan
    Pages 423-443
Back to top

Keywords

About this book

For the generation that reached sexual maturity in the 1960s, the “pill” became synonymous with sexual freedom and started a sexual revolution. For women it meant freedom from the fear of pregnancy, and for men enhanced sexual opportunity. The new era of the pill has nothing to do with fertility, but everything to do with sex. The first orally effective prescr- tion drug for treating erectile dysfunction (ED) was marketed in 1998. ® Sildenafil (Viagra ) has rejuvenated the aging male veterans of the sexual revolution, forever changed the science of sexual medicine, and tra- formed society’s perspective on aging and sex. This class of drugs, known as oral phosphodiesterase inhibitors (PDE-type 5), is highly effective in the treatment of ED. Since its introduction there has been a much greater awa- ness of ED, its comorbidities, and its effects on the quality of life. In 1997, while preparing to address the Endocrine Society on the occasion of the 92nd American Urological Association meeting, I first looked at the p- clinical studies of sildenafil. I thought “this will change everything” and it clearly has—changing practice patterns in sexual medicine, and the at- tudes of patients, potential patients, and their partners. Two new PDE-type ® ® 5 inhibitors, tadalafil (Cialis ) and vardenafil (Levitra ), were first approved by the European Committee for Proprietary Medicinal Products and subsequently by the Food and Drug Administration in 2003 and 2004.

Editors and Affiliations

  • Department of Urology, Mayo Clinic College of Medicine, Jacksonville

    Gregory A. Broderick

Bibliographic Information

  • Book Title: Oral Pharmacotherapy for Male Sexual Dysfunction

  • Book Subtitle: A Guide to Clinical Management

  • Editors: Gregory A. Broderick

  • Series Title: Current Clinical Urology

  • DOI: https://doi.org/10.1385/1592598714

  • Publisher: Humana Totowa, NJ

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: Humana Press 2005

  • Hardcover ISBN: 978-1-58829-451-7Published: 01 February 2005

  • Softcover ISBN: 978-1-61737-578-1Published: 09 December 2010

  • eBook ISBN: 978-1-59259-871-7Published: 06 November 2007

  • Series ISSN: 2197-7194

  • Series E-ISSN: 2197-7208

  • Edition Number: 1

  • Number of Pages: 464

  • Number of Illustrations: 100 b/w illustrations

  • Topics: Urology

Publish with us

Policies and ethics

Back to top

Search

Navigation